Physician profile
Glen Diaz
NPI 1780773952
$3,121.14
in general payments reported to CMS, 2019-2025
27 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $1,774 · 2023: $271 · 2024: $358 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,497.17 | 2022 | |
| Pfizer INC. | $312.13 | 2021-2025 | |
| Corium, LLC | $196.74 | 2021-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $171.13 | 2024-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $120.11 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sobi, INC | $99.47 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $78.91 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $77.24 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $66.57 | 2023-2024 | Flumist Quadrivalent |
| Kaleo, INC. | $51.35 | 2021-2022 | |
| Cranial Technologies, INC | $47.16 | 2024-2025 | Doc Band |
| Seqirus USA INC | $41.22 | 2022-2025 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $34.71 | 2024-2025 | Relexxii |
| Sanofi Pasteur INC. | $33.60 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $33.35 | 2021 | |
| Glaxosmithkline, LLC. | $28.28 | 2022-2023 | Bexsero |
| Ultragenyx Pharmaceutical INC. | $28.08 | 2021-2023 | |
| Alk-Abello, INC | $16.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.85 | 2024 | |
| Genentech USA, INC. | $15.80 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.02 | 2024 | |
| Biomarin Pharmaceutical INC. | $14.93 | 2024 | Voxzogo 1.2mg |
| Galderma Laboratories, L.P. | $14.60 | 2021 | |
| Sage Therapeutics, LLC | $13.88 | 2021 | |
| Tris Pharma INC | $13.59 | 2025 | Dyanavel Xr |
| Organon LLC | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.